- Home
- AACT vs GHRS Comparison
AACT vs GHRS Comparison
Compare AACT & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACT
- GHRS
- Stock Information
- Founded
- AACT 2021
- GHRS 2018
- Country
- AACT United States
- GHRS Ireland
- Employees
- AACT N/A
- GHRS N/A
- Industry
- AACT
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- AACT
- GHRS Health Care
- Exchange
- AACT Nasdaq
- GHRS Nasdaq
- Market Cap
- AACT 705.2M
- GHRS 774.1M
- IPO Year
- AACT 2023
- GHRS 2021
- Fundamental
- Price
- AACT $11.40
- GHRS $12.90
- Analyst Decision
- AACT
- GHRS Strong Buy
- Analyst Count
- AACT 0
- GHRS 8
- Target Price
- AACT N/A
- GHRS $30.63
- AVG Volume (30 Days)
- AACT 538.2K
- GHRS 194.6K
- Earning Date
- AACT 01-01-0001
- GHRS 11-13-2025
- Dividend Yield
- AACT N/A
- GHRS N/A
- EPS Growth
- AACT N/A
- GHRS N/A
- EPS
- AACT 0.26
- GHRS N/A
- Revenue
- AACT N/A
- GHRS N/A
- Revenue This Year
- AACT N/A
- GHRS N/A
- Revenue Next Year
- AACT N/A
- GHRS N/A
- P/E Ratio
- AACT $43.55
- GHRS N/A
- Revenue Growth
- AACT N/A
- GHRS N/A
- 52 Week Low
- AACT $10.80
- GHRS $6.00
- 52 Week High
- AACT $11.62
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- AACT 48.97
- GHRS 47.20
- Support Level
- AACT $11.38
- GHRS $12.36
- Resistance Level
- AACT $11.44
- GHRS $13.37
- Average True Range (ATR)
- AACT 0.02
- GHRS 0.78
- MACD
- AACT -0.00
- GHRS -0.06
- Stochastic Oscillator
- AACT 25.00
- GHRS 38.77
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.